Home / Pharmacology / Enzyme-Linked Receptors / Receptor Tyrosine Kinases (RTKs) / VEGFR / VEGFR Inhibitors / Ki 8751

Ki 8751

Cat. No. 2542 3 Citations Submit a Review Datasheet / COA / SDS
Pricing Availability   Qty
Description: Potent, selective VEGFR-2 inhibitor
Chemical Name: N-(2,4-Difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]urea
Purity: ≥97% (HPLC)
Datasheet
Citations (3)
Reviews
Literature (1)
Pathways (1)
Biological Activity Technical Data Solubility Calculators Datasheets References

Biological Activity for Ki 8751

Ki 8751 is a potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC50 = 0.9 nM). Displays some inhibitory activity towards c-Kit, PDGFRα and FGFR-2 (IC50 values range from 40 to 170 nM) but is highly selective over other receptor tyrosine kinases (IC50 > 10000 nM for FGFR-2, EGFR and HGFR). Inhibits VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC) and inhibits tumor growth in vivo; antiangiogenic.

Compound Libraries for Ki 8751

Ki 8751 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Kinase Inhibitor Library. Find out more about compound libraries available from Tocris.

Technical Data for Ki 8751

M. Wt 469.41
Formula C24H18F3N3O4
Storage Store at +4°C
Purity ≥97% (HPLC)
CAS Number 228559-41-9
PubChem ID 11317348
InChI Key LFKQSJNCVRGFCC-UHFFFAOYSA-N
Smiles COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=CC=C(F)C=C4F)C(F)=C3)=CC=NC2=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Ki 8751

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 46.94 100

Preparing Stock Solutions for Ki 8751

The following data is based on the product molecular weight 469.41. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.13 mL 10.65 mL 21.3 mL
5 mM 0.43 mL 2.13 mL 4.26 mL
10 mM 0.21 mL 1.07 mL 2.13 mL
50 mM 0.04 mL 0.21 mL 0.43 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for Ki 8751

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet

References for Ki 8751

References are publications that support the biological activity of the product.

Kubo et al (2005) Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumour activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J.Med.Chem. 48 1359 PMID: 15743179

If you know of a relevant reference for Ki 8751, please let us know.

View Related Products by Target

View Related Products by Product Action

View all VEGFR Inhibitors

Keywords: Ki 8751, Ki 8751 supplier, Potent, selective, VEGFR-2, inhibitors, inhibits, Vascular, Endothelial, Growth, Factors, Receptors, KDR, Flt, Receptor, Tyrosine, Kinases, RTKs, Ki8751, VEGFR, 2542, Tocris Bioscience

3 Citations for Ki 8751

Citations are publications that use Tocris products. Selected citations for Ki 8751 include:

Marino et al (2018) Regulation of breast cancer induced bone disease by cancer-specific IKKβ. Oncotarget 9 16134 PMID: 29662632

Kawakami et al (2011) Investigation of a novel molecular descriptor for the lead optimization of 4-aminoquinazolines as vascular endothelial growth factor receptor-2 inhibitors: application for quantitative structure-activity relationship analysis in lead optimization. J Neurosci 21 1371 PMID: 21306896

Page et al (2019) Positive Feedback Defines the Timing, Magnitude, and Robustness of Angiogenesis. Cell Rep 27 3139 PMID: 31189101

Do you know of a great paper that uses Ki 8751 from Tocris? Please let us know.

Reviews for Ki 8751

There are currently no reviews for this product. Be the first to review Ki 8751 and earn rewards!

Have you used Ki 8751?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Angiogenesis in Cancer Poster

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.

Pathways for Ki 8751

VEGF Signaling Pathway

VEGF Signaling Pathway

VEGF signaling pathway is involved in embryonic vascular development (vasculogenesis) and in the formation of new blood vessel (angiogenesis). It also induces cell migration, proliferation and survival.